Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Heart Failure 3Cardiotoxicity 2Breast Neoplasms 2Thyroid cancer, medullary 1Neoplasms, Second Primary 1Carcinoma, Medullary 1Breast Diseases 1

Interventions

Letrozole 5pyrotinib 4Trastuzumab 4Anastrozole 4palbociclib 3exemestane 2abemaciclib 2Sodium Chloride 2Exercise 2Epirubicin 2Drug Evaluation 2Docetaxel 2Cyclophosphamide 2Botulinum Toxins, Type A 2Blood Specimen Collection 2Aromatase Inhibitors 2sacubitril and valsartan sodium hydrate drug combination 1ribociclib 1pertuzumab 1gadoterate meglumine 1Vinorelbine 1Tomography, X-Ray Computed 1Tamoxifen 1Surveys and Questionnaires 1Surgimend 1Surgical Procedures, Operative 1Paclitaxel 1Mammaplasty 1Liquid Biopsy 1Leflunomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Diseases × sacubitril and valsartan sodium hydrate drug combination × Clear all
NCT05465031 2025-03-14

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Silesian Centre for Heart Diseases

Phase 4 Recruiting
600 enrolled
Breast

Breast Diseases, Breast Neoplasms, Heart Failure, Neoplasms, Second Primary, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡